








The Future of Pharmaceutical Labelling: Updates on Malaysia's e-Labelling Initiative


THE 14TH APAC
22 APRIL 2025 | TUESDAY | TOKYO, JAPAN

Maslinda Mahat
National Pharmaceutical Regulatory Agency (NPRA)
Ministry of Health Malaysia

PRESENTATION OUTLINE

01	e-Labelling milestones in Malaysia	
02	The implementation	
03	The preliminary findings	
04	Recommendations based on the preliminary findings	
05	Way forward	


E-LABELLING MILESTONES IN MALAYSIA




PhAMA: Pharmaceutical Association of Malaysia
MOPI: The Malaysian Organisation of Pharmaceutical Industries
MAPS: Malaysian Association of Pharmaceutical Suppliers

THE IMPLEMENTATION (1)

QR CODE SCAN



NPRA QUEST SYSTEM OF THE PRODUCT:



PRODUCT INFORMATION FROM NPRA QUEST SYSTEM:

- Product Name
- Registration Number
- Holder & Address
- Manufacturer & Address
- Importer & Address
- Ingredient Information
- Packaging Information
- Product Label
- Package Insert
- Consumer Medication Information Leaflet (RiMUP)

DATA CARRIER:
QR CODE

DATA FORMAT:
PDF

HOSTING SITE:
NPRA QUEST SYSTEM

THE IMPLEMENTATION (2)


VOLUNTARY PHASE



Product scope:

- 1) **Biologics**
- 2) **New drug products**
- 3) **Generic products containing scheduled Poison**

NO. OF E-LABELLING APPLICATIONS APPROVED (as of 31 March 2025)



TOTAL: 542 products

THE IMPLEMENTATION (3)

- ❖ An ongoing study is being conducted by a local university, involving pharmaceutical industries and healthcare professionals (HCP).
- ❖ Objectives:
To evaluate the readiness of the pharmaceutical industries and the acceptance by the HCP regarding the implementation

The findings will guide policy decisions regarding the implementation approach (voluntary vs. mandatory) and the scope of the product

THE PRELIMINARY FINDINGS

(Period: December 2024 – 5 April 2025)

Respondents:
170 HCPs +
5 pharmaceutical
companies

Pharmaceutical industries perspectives

Healthcare professionals perspectives

Readiness

Most companies are
technically ready

Willing to adopt with sufficient
training and offline access
solutions

Key challenges

ASEAN regulatory
harmonisation:
some ASEAN countries still do
not accept e-labelling

Concern about the digital
divide, especially among the
elderly and disabled

Platform preferences

NPRA QUEST system

Must be mobile and
offline friendly

RECOMMENDATIONS BASED ON THE PRELIMINARY FINDINGS

SHORT TERM



- Maintain voluntary phase
- Deliver targeted training to healthcare professionals (HCPs)

MEDIUM TERM



- Improve public awareness
- Publish assessable user guide for the HCPs

LONG TERM



- Promote ASEAN standardisation on e-labelling
- Expand scope to cover Non-Prescription Medicine and Health Supplements

WAY FORWARD

1

To extend the product scope to include Non-Prescription Medicines (e.g. Paracetamol, vitamins)
→ Q3 2025

2

To increase the publicity on the e-labelling implementation among healthcare professionals

3

To discuss e-labelling implementation in ASEAN Pharmaceutical Product Working Group



ACKNOWLEDGEMENT:

**Members of the
e-Labelling Task Force**

**The local university
conducting the study**



MOH: Ministry of Health Malaysia including NPRA
PhAMA: Pharmaceutical Association of Malaysia
MOPI: The Malaysian Organisation of Pharmaceutical Industries
MAPS: Malaysian Association of Pharmaceutical Suppliers

THANK YOU FOR YOUR ATTENTION



+603-7883 5400 (General line)
+603-7883 5416



maslinda@npra.gov.my



<http://www.npra.gov.my>